Roche and Antisoma's R1549 drug fails in trials - future in doubt; Aventis will say "yes" to Sanofi's merger proposal; Two companies, two smallpox vaccines, two different results; GLP-1 conjugate encouraging in Phase II trial; SSX antigens present novel cancer vacine targets; Bacteriophage enzyme gives clues toward possible cancer therapy; Potential vaccine vector engineered from adenovirus and reovirus; Crystal structure obtained for anthrax toxin receptor protein; Superoxide dismutase dimers look promising as target in ALS; Polio vaccine/HIV link again refuted.
展开▼
